Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVC-101 |
Synonyms | |
Therapy Description |
MVC-101 is a bispecific T cell engager that targets EGFR expressed on tumor cells and CD3 antigen found on T cells, which upon proteolytic cleavage of the linker potentially leads to T cell activation against tumor cells and subsequent tumor regression (PMID: 32684124). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVC-101 | MVC 101|MVC101|TAK 186|TAK-186|TAK186 | CD3 Antibody 99 EGFR Antibody 60 | MVC-101 is a bispecific T cell engager that targets EGFR expressed on tumor cells and CD3 antigen found on T cells, which upon proteolytic cleavage of the linker potentially leads to T cell activation against tumor cells and subsequent tumor regression (PMID: 32684124). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | USA | GBR | AUS | 1 |